Yubao Wang

Yubao Wang

Auto-generated profile, based on publicly available information

Yubao Wang

Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CFCarmine Fedele
Carmine Fedele
SLShuai Li
Shuai Li
KTKai Wen Teng
Kai Wen Teng
CFConnor J.R. Foster
Connor J.R. Foster
DPDavid Peng
David Peng
BNBenjamin G. Neel
Benjamin G. Neel
KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react with Cys-12 (G12C-Is). Using new affinity reagents to monitor KRASG12C activation and inhibitor engagement, we found that an SHP2 inhibitor (SHP2-I) increases KRAS-GDP occupancy, enhancing G12C-I efficacy. The SHP2-I abrogated RTK feedback signaling and adaptive resistance to G12C-Is in vitro, in xenografts, and in syngeneic KRASG12C-mutant pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). SHP2-I/G12C-I combination evoked favorable but tumor site–specific changes in the immune microenvironment, decreasing myeloid suppressor cells, increasing CD8+ T cells, and sensitizing tumors to PD-1 blockade. Experiments using cells expressing inhibitor-resistant SHP2 showed that SHP2 inhibition in PDAC cells is required for PDAC regression and remodeling of the immune microenvironment but revealed direct inhibitory effects on tumor angiogenesis and vascularity. Our results demonstrate that SHP2-I/G12C-I combinations confer a substantial survival benefit in PDAC and NSCLC and identify additional potential combination strategies.

1 March 2022 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
FMFrancesco Maura
Francesco Maura
EBEileen M. Boyle
Eileen M. Boyle
EREven H. Rustad
Even H. Rustad
CACody Ashby
Cody Ashby
DKDavid Kaminetzky
David Kaminetzky
GMGareth John Morgan
Gareth John Morgan

3 April 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
Ali SASSIAli SASSI
Ali SASSI
YWYubao Wang
Yubao Wang
ACAlexandra Chassot
Alexandra Chassot
OKOlga Komarynets
Olga Komarynets
IRIsabelle Roth
Isabelle Roth
EFEric Feraille
Eric Feraille
Significance Statement: In the renal collecting duct, fluid and solute reabsorption are the result of both transcellular and paracellular transport. Although the mechanisms of transcellular transport have been extensively studied, less is known regarding the regulation of the paracellular pathway. The authors investigated the physiologic role and regulation of the transmembrane protein claudin-8 in cultured mouse cortical collecting duct cell models and in knockout mice lacking kidney tubule–specific expression of the epithelial sodium channel γ-subunit, discovering an interaction between the γ-subunit and claudin-8. This interaction modulates paracellular permeability to sodium and may play an important role in preventing the backflow of reabsorbed solutes and water to the tubular lumen, as well as in coupling paracellular and transcellular sodium transport. Background: Water and solute transport across epithelia can occur via the transcellular or paracellular pathways. Tight junctions play a key role in mediating paracellular ion reabsorption in the kidney. In the renal collecting duct, which is a typical absorptive tight epithelium, coordination between transcellular sodium reabsorption and paracellular permeability may prevent the backflow of reabsorbed sodium to the tubular lumen along a steep electrochemical gradient. Methods: To investigate whether transcellular sodium transport controls tight-junction composition and paracellular permeability via modulating expression of the transmembrane protein claudin-8, we used cultured mouse cortical collecting duct cells to see how overexpression or silencing of epithelial sodium channel (ENaC) subunits and claudin-8 affect paracellular permeability. We also used conditional kidney tubule–specific knockout mice lacking ENaC subunits to assess the ENaC’s effect on claudin-8 expression. Results: Overexpression or silencing of the ENaC γ-subunit was associated with parallel and specific changes in claudin-8 abundance. Increased claudin-8 abundance was associated with a reduction in paracellular permeability to sodium, whereas decreased claudin-8 abundance was associated with the opposite effect. Claudin-8 overexpression and silencing reproduced these functional effects on paracellular ion permeability. Conditional kidney tubule–specific ENaC γ-subunit knockout mice displayed decreased claudin-8 expression, confirming the cell culture experiments' findings. Importantly, ENaC β-subunit or α-subunit silencing or kidney tubule–specific β-ENaC or α-ENaC knockout mice did not alter claudin-8 abundance. Conclusions: Our data reveal the specific coupling between ENaC γ-subunit and claudin-8 expression. This coupling may play an important role in preventing the backflow of reabsorbed solutes and water to the tubular lumen, as well as in coupling paracellular and transcellular sodium permeability.

4 September 2025 in Blood
Verified
Journal Article
Closed access
DGDylan C. Gagler
Dylan C. Gagler
HGHussein Ghamlouch
Hussein Ghamlouch
DZDi Zhang
Di Zhang
PBPatrick Blaney
Patrick Blaney
ATAvital Tenenbaum
Avital Tenenbaum
GMGareth J. Morgan
Gareth J. Morgan
We carried out a single-cell multiomic analysis on a series of MYD88-mutated Waldenström macroglobulinemia (WM) patients and identified 2 distinct subtypes of disease, memory B-cell (MBC)–like and plasma cell (PC)–like, based on their expression of key lineage defining genes. Biologically, the subtypes are characterized by their variable capacity to differentiate fully toward a PC and exhibit unique transcriptomic, chromatin accessibility, and genomic profiles. The MBC-like subtype is unable to differentiate beyond the MBC stage, upregulates key MBC genes, and is characterized by upregulated B-cell receptor and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling. In contrast, the PC-like subtype can partially differentiate toward a PC, upregulates key PC genes, has enhanced NF-κB signaling, and has an upregulated unfolded protein response. Pseudotime trajectory analysis of combined single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin with sequencing supports the variable differentiation capacity of each subtype and implicate key transcription factors SPI1, SPIB, BCL11A, and XBP1 in these features. The existence and generalizability of the 2 disease subtypes were validated further using hierarchical clustering of bulk RNA-sequencing data from a secondary set of patients. The biological significance of the subtypes was further established using whole-genome sequencing, in which it was shown that CXCR4, NIK, and ARID1A mutations occur predominantly in the MBC-like subtype, and 6q deletions in the PC-like subtype. We conclude that the variable differentiation blockade seen in WM manifests itself clinically as 2 disease subtypes with distinct epigenetic, mutational, transcriptional, and clinical features, with potential implications for WM treatment strategies.

14 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EBEileen M. Boyle
Eileen M. Boyle
PBPatrick Blaney
Patrick Blaney
JSJames H. Stoeckle
James H. Stoeckle
YWYubao Wang
Yubao Wang
HGHussein Ghamlouch
Hussein Ghamlouch
GMGareth John Morgan
Gareth John Morgan
Purpose: Chromosome 1 (chr1) copy-number abnormalities (CNA) and structural variants (SV) are frequent in newly diagnosed multiple myeloma (NDMM) and are associated with a heterogeneous impact on outcomes, the drivers of which are largely unknown. Experimental Design: A multiomic approach comprising CRISPR, gene mapping of CNAs and SVs, methylation, expression, and mutational analysis was used to document the extent of chr1 molecular variants and their impact on pathway utilization. Results: We identified two distinct groups of gain(1q): focal gains associated with limited gene-expression changes and a neutral prognosis, and whole-arm gains, which are associated with substantial gene-expression changes, complex genetics, and an adverse prognosis. CRISPR identified a number of dependencies on chr1 but only limited variants associated with acquired CNAs. We identified seven regions of deletion, nine of gain, three of chromothripsis (CT), and two of templated insertion (TI), which contain a number of potential drivers. An additional mechanism involving hypomethylation of genes at 1q may contribute to the aberrant gene expression of a number of genes. Expression changes associated with whole-arm gains were substantial and gene set enrichment analysis identified metabolic processes, apoptotic resistance, signaling via the MAPK pathway, and upregulation of transcription factors as being key drivers of the adverse prognosis associated with these variants. Conclusions: Multiple layers of genetic complexity impact the phenotype associated with CNAs on chr1 to generate its associated clinical phenotype. Whole-arm gains of 1q are the critically important prognostic group that deregulate multiple pathways, which may offer therapeutic vulnerabilities.

19 June 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
EBEileen M. Boyle
Eileen M. Boyle
LWLouis Williams
Louis Williams
PBPatrick Blaney
Patrick Blaney
CACody Ashby
Cody Ashby
Michael Anton BauerMichael Anton Bauer
Michael Anton Bauer
GMGareth John Morgan
Gareth John Morgan